CDKN2A and hepatocellular carcinoma: Sarcomatoid HCC showed significant higher mutation rates in CDKN2A (26.6% vs. 4.0%, p = 0.024), EPHA5 (13.3% vs. 0%, p = 0.026), FANCM (13.3% vs. 0%, p = 0.026), and MAP3K1 (13.3% vs. 0%, p = 0.026) than non‐sarcomatoid HCC.